At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,223 enrolled
Drug / intervention
Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)drug
Likely dose
Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination) 5 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Regulatory Required Non Interventional Study to Monitor the Safety and Effectiveness of Once Daily Treatment of Orally Inhaled Vahelva Respimat (Tiotropium + Olodaterol Fixed Dose Combination 2.5µg/2.5µg Per Puff (2 Puffs Comprise One Medicinal Dose)) for Korean Patients With COPD (Chronic Obstructive Pulmonary Disease)
In Brief
An observational study evaluating Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination) for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 3,223 participants across 1 site.
Detailed Summary
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartDec 2016
Primary CompletionJan 2021
TodayJul 2026
First PostedAug 12, 2016
Enrollment StartDec 19, 2016
Primary CompletionJan 20, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 9.9 years ago
Interventions
Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)drug
The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.